Regen BioPharma Inc (RGBP)
Regen BioPharma Inc is a healthcare company focused on regenerative medicine and biotechnology research in the United States. The company works on identifying small molecules that can inhibit or express NR2F6, a target it links to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. Its development pipeline includes HemaXellarate, a cellular therapeutic derived from autologous stromal vascular fraction taken from adipose tissue, as well as dCellVax, tCellVax, DiffronC, and DuraCAR, each built around different cell-based or RNA-interference approaches. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California. The listed security is common stock traded on OTC Markets under the symbol RGBP.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-RGBP
|
Not available
|
Not available
|
Not available
|
Weak
|
0.0%
|
October 28, 2026
|
0.7x
|
167.527 K
|
1.075 M
|
83.0%
|
97.0%
|
-141.5
|
37.5%
|
